Koreen A R, Lieberman J A, Alvir J, Chakos M
Hillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine. Glen Oaks, NY 11004, USA.
Neuropsychopharmacology. 1997 Jan;16(1):61-8. doi: 10.1016/S0893-133X(96)00160-1.
Although there has been renewed interest in the serotonin (5-HT) system in schizophrenia, direct evidence for 5-HT dysfunction is limited. This study compares the responses of m-chlorophenyl-piperazine (mCPP), a 5-HT agonist, in first-episode schizophrenia and a known psychotogenic dopamine agonist, methylphenidate. Eighteen patients experiencing their first episode of psychosis and eight healthy controls received methylphenidate (0.5 mg/kg) and mCPP (0.1 mg/kg) intravenously. Behavioral assessments were done before and after the procedure, and a peak response to each agent was rated. Methylphenidate, but not mCPP, produced psychotic symptoms in patients. mCPP did decrease anxiety, hallucinations, and anger and increased agitation, somatic concern, and impaired understandability. Both agents had limited effects on controls. In conclusion, unlike methylphenidate, mCPP did not produce psychotic symptom activation in schizophrenic patients in, and its effects appeared to be nonspecific.
尽管精神分裂症患者血清素（5-羟色胺，5-HT）系统再次受到关注，但5-HT功能障碍的直接证据仍然有限。本研究比较了5-HT激动剂间氯苯哌嗪（mCPP）与已知致幻多巴胺激动剂哌醋甲酯在首发精神分裂症患者中的反应。18例首次发作精神病的患者和8名健康对照者静脉注射哌醋甲酯（0.5mg/kg）和mCPP（0.1mg/kg）。在给药前后进行行为评估，并对每种药物的峰值反应进行评分。哌醋甲酯可使患者产生精神病性症状，但mCPP不会。mCPP确实可减轻焦虑、幻觉和愤怒，并增加激越、躯体不适及言语清晰度受损。两种药物对健康对照者的影响均有限。总之，与哌醋甲酯不同，mCPP不会在精神分裂症患者中引发精神病性症状激活，其作用似乎是非特异性的。
